Serum levels of C‐peptide, IGFBP‐1 and IGFBP‐2 and endometrial cancer risk; Results from the European prospective investigation into cancer and nutrition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
We conducted a case‐control study nested within the European Prospective Investigation into Cancer and Nutrition, to examine the associations between prediagnostic serum concentrations of C‐peptide, insulin‐like growth factor binding protein (IGFBP)‐1 and IGFBP‐2, and endometrial cancer risk. Among pre‐ and post‐menopausal women, who were not currently using exogenous hormones, 286 women developed incident endometrial cancer during an average 5.1 years follow‐up. Using risk set sampling, 555 matched control subjects were selected. In conditional logistic regression models adjusted for matching factors only, endometrial cancer risk increased with increasing serum levels of C‐peptide (relative risks (RR) for the top vs. bottom quartile = 2.13 [95% confidence interval (CI) 1.33–3.41], ptrend = 0.001, and decreasing serum levels of IGFBP‐2 (RR for the top vs. bottom quartile = 0.56 [95% CI 0.35–0.90], ptrend = 0.03, but was not significantly associated with IGFBP‐1 levels (RR for the top vs. bottom quartile = 0.76 [95% CI 0.47–1.21], ptrend = 0.25). In BMI‐adjusted models, only the C‐peptide association remained marginally statistically significant (RR for the top vs. bottom quartile = 1.56 [95% CI 0.94–2.57], ptrend = 0.05 for C‐peptide; 0.84 [95% CI 0.50–1.40], ptrend = 0.74 for IGFBP‐2; and 1.08 [95% CI 0.65–1.78], ptrend = 0.86 for IGFBP‐1 levels). These associations were stronger among nonfasting women (≤≤6 hr since last meal; 63% of subjects) but were not evident among fasting women, although the interactions were not statistically significant. The C‐peptide‐risk association was substantially attenuated after adjustment for free estradiol in postmenopausal women (RR for the top vs. bottom quartile = 1.28 [95% CI 0.67–2.45], ptrend = 0.42. Our results provide modest support to the hypothesis that hyperinsulinaemia is a risk factor for endometrial cancer. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Self-citationRiboli, E., Hunt, K., Slimani, N., Ferrari, P., Norat, T., Fahey, M., Charrondière, U., Hémon, B., Casagrande, C., Vignat, J., et al. (2002) · Public Health Nutrition · doi:10.1079/phn2002394 · Cited by 1,866 · cited 1×
“EPIC recruitment procedures and collection of questionnaire data, anthropometric measurements and blood samples have been previously described in detail.(20) In brief, extensive standardized questionnaire data were collected between 1992 and 1998, from 366,500 women and 153,500 men in 10 western European countries, of…”
MethodSelf-citationAge- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts
The DECODE Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.1.61 · Cited by 608
Insulin-like Growth Factor Binding Protein-1: Recent Findings and New Directions
Lee, P. D. K., Giudice, L. C., Conover, C. A., & Powell, D. R. (1997) · Experimental Biology and Medicine · doi:10.3181/00379727-216-44182 · Cited by 523 · cited 3×
“Lower IGFBP-1 and IGFBP-2 levels may lead to increased IGF-I bioavailability in the circulation and endometrial tissue,(2,11,13,41,43) because contrary to IGFBP-3, IGFBP-1 and IGFBP-2 can combine with IGF-I to form a small complex that can cross the capillary endothelium and prevent IGF-I receptor binding.(11,12,14,40…”
BackgroundResultAllen, N. E., Appleby, P. N., Kaaks, R., Rinaldi, S., Davey, G. K., & Key, T. J. (2003) · Cancer Causes & Control · doi:10.1023/a:1022518321634 · Cited by 104
Self-citation
Cited by
Obesity as a Major Risk Factor for Cancer
De Pergola, G., & Silvestris, F. (2013) · Journal of Obesity · doi:10.1155/2013/291546 · Cited by 959
The proliferating role of insulin and insulin-like growth factors in cancer
Gallagher, E. J., & LeRoith, D. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.007 · Cited by 380
Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies
Pisani, P. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801954451 · Cited by 329
Body mass index, hormone replacement therapy, and endometrial cancer risk: A meta-analysis
Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M., & Renehan, A. G. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0832 · Cited by 321
Hyperinsulinemia in Obesity, Inflammation, and Cancer
Zhang, A. M. Y., Wellberg, E. A., Kopp, J. L., & Johnson, J. D. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0250 · Cited by 305
Metadata
- Authors
- Cust, A. E., Allen, N. E., Rinaldi, S., Dossus, L., Friedenreich, C., Olsen, A., Tjønneland, A., Overvad, K., Clavel‐Chapelon, F., Boutron‐Ruault, M., Linseisen, J., Chang‐Claude, J., Boeing, H., Schulz, M., Benetou, V., Trichopoulou, A., Trichopoulos, D., Palli, D., Berrino, F., Tumino, R., Mattiello, A., Vineis, P., Quirós, J. R., Agudo, A., Sánchez, M., Larrañaga, N., Navarro, C., Ardanaz, E., Bueno‐de‐Mesquita, H. B., Peeters, P. H. M., van Gils, C. H., Bingham, S., Khaw, K., Key, T., Slimani, N., Riboli, E., & Kaaks, R.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2007-04-10
- Volume
- 120
- Issue
- 12
- Pages
- 2656-2664
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2039819173
- Cited by
- 102
- References
- 5
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.